TCM
SGMO

Tradewinds Capital Management’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Tradewinds Capital Management’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10
Closed – – 729
2022
Q1 		$0 Hold
10
– – ﹤0.01% 831
2021
Q4 		$0 Hold
10
– – ﹤0.01% 807
2021
Q3 		$0 Hold
10
– – ﹤0.01% 797
2021
Q2 		$0 Hold
10
– – ﹤0.01% 810
2021
Q1 		$0 Buy
+10
New +$135 ﹤0.01% 777

Other funds holding SGMO

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
RCMU
Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Tradewinds Capital Management's SGMO Position: Q2 2022 in Review

Tradewinds Capital Management sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2022, closing a stake of 10 shares.

Tradewinds Capital Management first reported a position in SGMO in Q1 2021 and held it in 5 quarters. The position peaked at $0 in Q1 2022. 188 funds tracked by Wall St. Rank hold SGMO as of Q2 2022.

  • Tradewinds Capital Management reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2022 after selling out during the quarter.
  • Tradewinds Capital Management sold 10 SANGAMO THERAPEUTICS INC shares in Q2 2022.
  • Tradewinds Capital Management first reported a position in SANGAMO THERAPEUTICS INC in Q1 2021 and held it in 5 quarters.
  • Tradewinds Capital Management's SANGAMO THERAPEUTICS INC position peaked at $0 in Q1 2022.
  • 188 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2022.

Based on Tradewinds Capital Management's 13F filing for Q2 2022, filed 21 Jul 2022.